For disorders driven by a known genetic component, research understandably focuses on developing a drug targeting that genetic signature. When that works, the outcome benefits patients but the end ...

(A) Suppressor tRNA readthrough strategy. Natural tRNAs with engineered anticodons are charged with canonical amino acids to enable readthrough of the premature termination codon (PTC). (B) Unnatural ...

Alltrna is advancing a new class of genetic medicines based on the power of tRNA biology to universally treat Stop Codon Disease, which encompasses thousands of genetic diseases caused by a premature ...

Peking University, June 27, 2025: To overcome the inherent challenge of translation termination interference caused by stop codon reprogramming in mammalian cells, researchers from Peking University ...

Alltrna Inc. raised $109 million in a series B round to back its work with transfer RNA, with the first targeted indication of stop codon disease: a condition that takes in thousands of rare and ...

To overcome the inherent challenge of translation termination interference caused by stop codon reprogramming in mammalian cells, researchers from Peking University led by Chen Peng from College of ...